Almost 70% of GLP-1 Users Report Cost as Key Influence on Treatment Decisions 

Navitus surveyed 2,000 Americans, finding nearly 70% of GLP-1 users say cost influenced starting or continuing treatment, with 44% reporting higher-than-expected expenses and cost as the top reason for discontinuation. About 24% pay over $250 per prescription and around 8% pay at least $500, with weight-loss users more likely to face higher costs than those with type 2 diabetes.